How a Big Pharma Company Stalled a Potentially Lifesaving Vaccine in Pursuit of Bigger Profits

A vaccine against tuberculosis, the world’s deadliest infectious disease, has never been closer to reality, with the potential to save millions of lives. But its development slowed after its corporate owner focused on more profitable vaccines.

Related Keywords

South Africa ,Chile ,National Institutes Of Health ,Maryland ,United States ,Philadelphia ,Pennsylvania ,Netherlands ,Thailand ,Rockville ,Australia ,Brazil ,United Kingdom ,Montana ,Chilean ,America ,South African ,Luc Debruyne ,Julio Croda ,Tom Evans ,Mollie Simon ,Paul Sagan ,Glenda Gray ,Mike Frick ,Thomas Breuer ,Wolfgang Leitner ,Carl Alving ,Neil Martinson ,Thomas Scriba ,Emma Walmsley ,Jeremy Farrar ,Smithkline Beckman ,Steven Reed ,Cornell University ,World Health Organization ,Walter Reed Army Institute Of Research ,Gates Foundation ,Us Army ,Wellcome ,Treatment Action Group ,Department Of Veterans Affairs ,Drug Administration ,National Institute Of Allergy ,Melinda Gates Foundation ,Melinda Gates Medical Research Institute ,Tb Vaccine Accelerator Council ,Big Pharma ,Walter Reed Army Institute ,Veterans Affairs ,National Institutes ,Michel De Wilde ,Wellcome Trust ,South America ,Eastern Europe ,Accelerator Council ,National Institute ,Infectious Diseases ,Treatment Action ,